A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
Robert A Scott
, Daniel F Freitag
, Li Li
, Audrey Y Chu
, Praveen Surendran
, Robin Young
, Niels Grarup
, Alena Stancáková
, Yuning Chen
, Tibor V Varga
, Hanieh Yaghootkar
, Jian'an Luan
, Jing Hua Zhao
, Sara M Willems
, Jennifer Wessel
, Shuai Wang
, Nisa Maruthur
, Kyriaki Michailidou
, Ailith Pirie
, Sven J van der Lee
Christopher Gillson, Ali Amin Al Olama, Philippe Amouyel, Larraitz Arriola, Dominique Arveiler, Iciar Aviles-Olmos, Beverley Balkau, Aurelio Barricarte, Inês Barroso, Sara Benlloch Garcia, Joshua C Bis, Stefan Blankenberg, Michael Boehnke, Heiner Boeing, Eric Boerwinkle, Ingrid B Borecki, Jette Bork-Jensen, Sarah Bowden, Carlos Caldas, Muriel Caslake, L Adrienne Cupples, Carlos Cruchaga, Jacek Czajkowski, Marcel den Hoed, Janet A Dunn, Marit E Jørgensen, Allan Linneberg, Sune F Nielsen, Børge G Nordestgaard, Torben Jørgensen, CVD50 consortium
Dyk ned i forskningsemnerne om 'A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease'. Sammen danner de et unikt fingeraftryk.